Cardiac arrhythmia

Julien Barc, Jean-Jacques Schott and Vincent Probst


The primary objective of our group is to improve healthcare by combining basic research and clinical activity into translational research programs. Taking advantage of large pedigrees and one of the largest worldwide cohorts of patients suffering from inherited cardiac electrical disorders (Brugada syndrome, the long and short QT syndrome, the catecholaminergic polymorphic ventricular tachycardia, conduction defects, sinus dysfunction, idiopathic ventricular fibrillation and arrhythmogenic cardiomyopathy) we apply multi-omics screening strategies to establish clinical and genetic risk stratification for developing cardiac arrhythmia and prevent sudden cardiac death (SCD). The identification of new clinical and molecular markers from these ‘sensitized’ models of SCD are likely relevant to the broad problem of SCD.
Read more

  • NaV1.5-CARED project

NaV1.5-CARED European consortium proposes to capitalize on their largest worldwide cohorts of patients with inherited cardiac electrical and conduction defects (BrS and/or PCCD), to better predict the risk of (fatal) arrhythmia and conduction level at the individual level and characterize the molecular mechanism associating regulatory regions and genes with the cardiac diseases, with the goal to develop and validate innovative therapies to restore the function of NaV1.5 channel.
Read more

  • REGIOCARD project

Our strategy based on whole genome screening allows us to open unique opportunities to interrogate the full spectrum genetic variations. Furthermore we are particularly interested in investigating the role of variants in the non-coding regions of the genome, seat of the gene regulation. We then developed the REGIOCARD program on cardiac epigenetics to functionally annotate the human cardiac regulatory regions.
Read more

  • LEARN project
The translational research project LEARN combines multi-omics approach and phenotype characterization to decipher the molecular mechanism leading to a new syndrome associating cardiac electrical disorders and developmental defects. Large deletions, identified in 6 families, located in a gene desert area suggest the crucial role of a regulatory region. Based on human cardiomyocytes derived from iPSC and mouse model deleted for this regulatory region, we will investigate the role, targeted genes, the transcriptomic, electrophysiological consequences of this deleted regulatory element.
  • European Joint Programme on Rare Diseases: LQTS-NEXT
LQTS-NEXT will focus on the Long QT Syndrome (LQTS) as a model to test the hypotheses that (1) additional genetic factors as well as non-genetic parameters (clinical, ECG) conspire with the mutation to modulate disease severity, and (2) the incorporation of such additional genetic and non-genetic parameters in a risk prediction algorithm will provide a refined, personalized, assessment of risk. Furthermore, LQTS-NEXT will apply cutting edge genomic and bioinformatics approaches to identify the genetic defect underlying LQTS in patients that have remained mutation-negative after extensive gene panel testing of LQTS associated genes.
  • International research partnership GAINES and VERACITIES (FEDER Grant)

Our research takes place in a context of international collaborations allowing young scientists to interact with the world leaders in the field, follow training to acquire new skills and develop their network. 



Genome-wide association meta-analysis identifies novel Brugada Syndrome susceptibility loci and highlights a new mechanism of sodium channel regulation in disease susceptibility. Barc J*, Tadros R*, Glinge C*, Chiang DY*, Jouni M*, Simonet F*, [...], The International Brugada Syndrome Genetics Consortium, [...], Tanck MW, George AL Jr., MacRae CA, Burridge PW, Dina C, Probst V*, Wilde AA*, Schott JJ*, Redon R*, Bezzina CR*. Nat Genet (accepted)

Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome. Probst V, Goronflot T, Anys S, Tixier R, Briand J, Berthome P, Geoffroy O, Clementy N, Mansourati J, Jesel L, Dupuis JM, Bru P, Kyndt F, Wargny M, Guyomarch B, Thollet A, Mabo P, Gourraud PA, Behar N, Sacher F, Gourraud JB.Eur Heart J. 2021 May 1;42(17):1687-1695.

Progressive Atrial Conduction Defects Associated With Bone Malformation Caused by a Connexin-45 Mutation. Seki* A, Ishikawa* T, Daumy* X, Mishima H, Barc J, Sasaki R, Nishii K, Saito K, Urano M, Ohno S, Otsuki S, Kimoto H, Baruteau A-E, Thollet A, Fouchard S, Bonnaud S, Parent P, Shibata Y, Perrin J-P, Le Marec H, Hagiwara N, Mercier S, Horie M, Probst V, Yoshiura* K-I, Redon* R, Schott* J-J, Makita* N. J Am Coll Cardiol 2017;70:358–370.

Familial Catecholamine-Induced QT Prolongation in Unexplained Sudden Cardiac Death. Huchet* F, Kyndt* F, Barc* J, Thollet A, Charpentier F, Redon R, Schott JJ, le Marec H, Probst V, Gourraud JB. J Am Coll Cardiol 2017;69:1642–1643.

Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Bezzina CR*, Barc J*, Mizusawa Y*, Remme CA*, Gourraud J-B*, Simonet F, [...], Wilde AA*, Probst V*, Schott JJ*, Dina C*, Redon R*. Nat Genet 2013;45:1044–1049.


This programme has been financed by :

  • Académie des sciences/ Institut du France
  • Agence Nationale Recherche
  • CHU de Nantes
  • Direction Générale de l'Offre de soin (PHRC-I)
  • European Commission

  • FEDER Pays de la Loire
  • Fédération Française de Cardiologie
  • European Joint Programme on Rare Diseases
EUROPEAN 1 1 1 1
Mis à jour le 12 April 2024.